Product
RSP-1502
1 clinical trial
5 indications
Indication
Cystic Fibrosis LungIndication
Respiratory InfectionsIndication
RecurrentIndication
ChronicIndication
Pseudomonas aeruginosaClinical trial
A Double-Blind, Active-Controlled, Multiple-Ascending Dose, Phase 1b Study of Aerosolized RSP-1502 Delivered Via the PARI LC Plus® Nebulizer in Subjects With Cystic Fibrosis and Chronic Pseudomonas Aeruginosa Lung InfectionStatus: Recruiting, Estimated PCD: 2025-04-01